Press release
Glioma Market Projected to Reach USD 8.5 Billion by 2034
Glioma
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71173
Market Overview
• Market Size (2024): USD 4.6 billion
• Forecast (2034): USD 8.5 billion
• CAGR (2025-2034): 6.4%
Glioblastoma multiforme (GBM) remains the largest and most challenging segment, but innovation in immunotherapy and precision oncology is expanding treatment options across glioma subtypes.
Key Highlights:
• Increasing incidence of gliomas globally.
• Rising adoption of molecular diagnostics for classification and personalized treatment.
• Immunotherapy and targeted therapies driving pipeline growth.
• High unmet need due to limited curative therapies for aggressive gliomas.
Segmentation Analysis
By Product Type:
• Chemotherapy Agents (Temozolomide, Carmustine, Lomustine)
• Targeted Therapies (Bevacizumab, EGFR/VEGF inhibitors)
• Immunotherapies
o Immune Checkpoint Inhibitors
o Cancer Vaccines
o CAR-T Cell Therapy
• Radiation Therapies
• Surgical Devices & Instruments
By Platform:
• Small Molecules
• Biologics
• Cell & Gene Therapies
By Technology:
• Molecular Diagnostics & Biomarker Testing
• Image-Guided Surgery
• AI-Assisted Imaging & Treatment Planning
• Advanced Radiation Technologies (Proton Beam, Stereotactic Radiosurgery)
By End Use:
• Hospitals
• Specialty Cancer Centers
• Research Institutes
By Application:
• Glioblastoma Multiforme (GBM)
• Astrocytomas
• Oligodendrogliomas
• Ependymomas
• Others (rare gliomas, clinical research)
Segmentation Summary:
Chemotherapy and radiation remain standard, but targeted therapies and immunotherapies are reshaping the market. GBM dominates the application segment, while molecular diagnostics are essential for precision treatment approaches.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71173/glioma-market
Regional Analysis
North America
• Largest market with ~45% share in 2024.
• U.S. leads in clinical trials, molecular diagnostics, and immunotherapy adoption.
• Strong R&D funding from NIH and private oncology firms.
Europe
• Accounts for ~29% share.
• Germany, UK, and France leading in molecular pathology adoption.
• EU rare disease and oncology frameworks support glioma research.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.8%.
• Rising incidence of brain tumors in China, Japan, and India.
• Expanding oncology infrastructure and clinical trial networks.
Middle East & Africa
• Smaller share, limited by access to advanced oncology care.
• Growth supported by expanding tertiary hospitals in urban centers.
Latin America
• Brazil and Mexico lead the region.
• Rising availability of diagnostics and oncology therapies.
Regional Summary:
North America and Europe dominate with advanced diagnostics and therapy adoption, while Asia-Pacific offers the fastest growth due to increasing incidence and infrastructure expansion.
Market Dynamics
Key Growth Drivers:
• Rising global prevalence of gliomas, especially GBM.
• Expansion of precision oncology and biomarker-driven therapies.
• Strong clinical trial pipelines in immunotherapy and gene therapy.
• Advances in surgical and radiation technologies.
Key Challenges:
• High treatment costs and limited reimbursement in some regions.
• Poor prognosis and resistance to current therapies, especially in GBM.
• Small patient pool compared to other cancers, limiting large-scale R&D.
• Limited awareness and diagnosis in developing economies.
Latest Trends:
• Next-generation immunotherapies, including CAR-T and cancer vaccines.
• AI-driven imaging and machine learning for diagnosis and prognosis.
• Development of tumor-treating fields (TTF) devices as adjunctive therapy.
• Increasing collaborations between biotech firms and academic centers.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71173
Competitor Analysis
Major Players in the Market:
• F. Hoffmann-La Roche Ltd. (Bevacizumab)
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc. (Keytruda - immunotherapy)
• Amgen Inc.
• Bristol Myers Squibb (Opdivo - immunotherapy)
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• NovoCure Ltd. (Tumor Treating Fields)
Competitive Summary:
Roche, Novartis, and Merck lead in targeted therapies and immunotherapy, while NovoCure is pioneering tumor-treating fields for glioblastoma. BMS and Amgen are advancing checkpoint inhibitors and vaccine-based approaches. Competition is centered around innovation in precision medicine, immunotherapy, and AI-driven diagnostics.
Conclusion
The Glioma Market, valued at USD 4.6 billion in 2024, is projected to reach USD 8.5 billion by 2034, growing at a CAGR of 6.4%. Rising incidence, growing investment in R&D, and breakthroughs in immunotherapy and precision oncology will reshape treatment paradigms.
Key Takeaways:
• GBM dominates but has the highest unmet need, driving innovation in immunotherapies.
• North America and Europe lead in adoption, while Asia-Pacific grows fastest.
• Molecular diagnostics and AI are transforming early detection and treatment planning.
• CAR-T, cancer vaccines, and TTF devices represent key future opportunities.
The next decade will mark a shift in glioma management from conventional chemoradiotherapy to precision immunotherapies and advanced digital oncology tools, creating significant opportunities for pharma innovators, device makers, and healthcare providers.
This report is also available in the following languages : Japanese (神経膠腫市場), Korean (신경교종 시장), Chinese (胶质瘤市场), French (Marché du gliome), German (Gliommarkt), and Italian (Mercato del glioma), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71173/glioma-market#request-a-sample
Our More Reports:
Myelofibrosis Market
https://exactitudeconsultancy.com/reports/71443/myelofibrosis-market
Paroxysmal Hemoglobinuria Market
https://exactitudeconsultancy.com/reports/71445/paroxysmal-hemoglobinuria-market
Relapsed or Refractory Myelodysplastic Syndrome Market
https://exactitudeconsultancy.com/reports/71447/relapsed-or-refractory-myelodysplastic-syndrome-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioma Market Projected to Reach USD 8.5 Billion by 2034 here
News-ID: 4160025 • Views: …
More Releases from Exactitude Consultancy
Functional Dyspepsia Market Insights and Future Outlook
Introduction
Functional Dyspepsia (FD), often referred to as non-ulcer dyspepsia, is a chronic disorder characterized by persistent or recurrent pain and discomfort in the upper abdomen without any identifiable structural cause. Symptoms include bloating, nausea, early satiety, and epigastric pain, which significantly impact quality of life. FD is one of the most common functional gastrointestinal disorders, affecting millions worldwide, yet remains underdiagnosed and undertreated due to overlapping symptoms with other GI…
Malignant Pleural Mesothelioma Market Expected to Reach USD 910 Million by 2034
Malignant Pleural Mesothelioma (MPM) is a rare, aggressive cancer of the pleural lining of the lungs, most commonly caused by long-term asbestos exposure. Symptoms such as chest pain, shortness of breath, and pleural effusion often appear late, making early detection difficult. The disease is associated with poor prognosis, limited treatment options, and high mortality.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71175
Despite its rarity, MPM continues to be a…
Ascites Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Ascites is the abnormal accumulation of fluid in the peritoneal cavity, most commonly caused by advanced liver disease such as cirrhosis, but also associated with conditions like cancer, heart failure, and tuberculosis. It is a serious complication that often indicates end-stage organ dysfunction and contributes significantly to morbidity, mortality, and healthcare costs worldwide.
Management of ascites is complex and involves dietary modifications, diuretic therapy, paracentesis, and, in severe cases, transjugular intrahepatic…
Peptic Ulcer Market New Product Development & Latest Trends
Introduction
Peptic ulcers are open sores that develop on the inner lining of the stomach and the upper portion of the small intestine. They are primarily caused by Helicobacter pylori (H. pylori) infection, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), smoking, alcohol consumption, and stress-related factors. Symptoms include abdominal pain, bloating, indigestion, and, in severe cases, gastrointestinal bleeding or perforation.
Despite improved therapeutic options, peptic ulcers remain a major healthcare concern worldwide…
More Releases for GBM
Glioblastoma Multiforme (GBM) Treatment Market Report 2024: Trends and Projectio …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.66 billion In…
Goodpasture Syndrome (Anti-GBM Disease) With Excellent CAGR 5.30%
Goodpasture Syndrome Treatment market analysis report is a professional and a detailed market study focusing on primary and secondary drivers, market share, leading segments, and geographical analysis. This market report is a comprehensive background analysis of the ABC industry, which includes an assessment of the parental market. The report also aids in prioritizing market goals and attain profitable business. This analysis gives an examination of various segments that are relied…
Anti-GBM Autoantibody Disease Market - Embracing Immune Harmony: Anti-GBM Autoan …
Newark, New Castle, USA - new report, titled Anti-GBM Autoantibody Disease Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Anti-GBM Autoantibody Disease market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Anti-GBM Autoantibody Disease market. The report offers an overview of…
Glioblastoma Multiforme Treatment (GBM) Market: Trends, Opportunities & Regional …
The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and…
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…
